Is Insulin Glargine-aglr Injection (Rezvoglar Kwikpen) in shortage?
Insulin Glargine-aglr Injection is listed by FDA as being discontinued by at least one maker (updated Sep 1, 2026).
Every listed package
FDA tracks shortages per package. What each maker reports, most recently updated first:
- Rezvoglar, Injection, 100 [iU]/1 mL (NDC 0002-8980-05)
A business decision was made to discontinue manufacture of the drug. Distribution projected to end June 2027. If patients or prescribers have any questions, the Lilly Answers Center (1-800-545-5979) is available Monday through Friday from 9am to 8pm for assistance.
Maker contact: 800-545-5979
Insulin Glargine-aglr Injection shortage questions
Is Insulin Glargine-aglr Injection (Rezvoglar Kwikpen) in shortage?
Insulin Glargine-aglr Injection is listed by FDA as being discontinued by at least one maker (updated Sep 1, 2026).
What should I do if I can’t get Insulin Glargine-aglr Injection?
Don’t stop or ration it on your own. Ask your pharmacist whether another strength, package size or maker is in stock, and ask your prescriber about an alternative if none is.
Source: FDA Drug Shortages Database via openFDA. FDA notes that openFDA data is unvalidated and should not be used to make decisions about medical care; ask your pharmacist or prescriber before changing any medication. FDA Drug Shortages Database.